Beam Therapeutics Inc.BEAMNASDAQ

|||

Switch Symbol:

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 69% recommend buying.

Consensus Rating

Buy

26 analysts·High coverage

69%

Rating Distribution

Strong Buy

00%

Buy

1869%

Hold

727%

Sell

14%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 33% higher.

Bear Case

$28.00

+0%

Consensus

$37.20

+33%

Bull Case

$41.00

+47%

Price Range26 analysts

Low

Consensus

High

$28.00

$41.00

Current Target

Current Price

$27.89

Upside to Target

$9.31

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-4.67(12 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+39.94%

EPS—

FY2028

Rev+120.17%

EPS—

FY2029

Rev+220.41%

EPS—

Earnings Surprises

Beat rate:75%(9/12 quarters)

Avg surprise:+31.1%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 21, 2026Tudor Pickering

Beam Therapeutics Inc (BEAM) PT Raised at Bernstein Following Positive Regulatory Update

Target:$41.00

+32.2%from $31.00

Jan 20, 2026Bernstein

Beam Therapeutics price target raised to $41 from $37 at Bernstein

Target:$41.00

+32.4%from $30.96

Jan 7, 2026UBS

UBS Starts Beam Therapeutics Inc (BEAM) at Neutral

Target:$28.00

-1.2%from $28.34

Nov 24, 2025Evercore ISI

Beam Therapeutics initiated with an Outperform at Evercore ISI

Target:$35.00

+50.1%from $23.32

Oct 9, 2025Jefferies

Beam Therapeutics initiated with a Buy at Jefferies

Target:$41.00

+47.2%from $27.86

May 7, 2025Guggenheim

Beam Therapeutics price target lowered to $55 from $78 at Guggenheim

Target:$55.00

+244.0%from $15.99

Mar 3, 2025Scotiabank

Beam Therapeutics price target raised to $25 from $24 at Scotiabank

Target:$25.00

-0.4%from $25.10

Jan 7, 2025Tudor Pickering

Bernstein SocGen Group Upgrades Beam Therapeutics Inc (BEAM) to Outperform

Target:$37.00

+36.6%from $27.08

Nov 6, 2024Leerink Partners

Leerink Partners Upgrades Beam Therapeutics Inc (BEAM) to Outperform, 'we see a far more attractive risk/reward'

Target:$39.00

+60.3%from $24.34

Nov 5, 2024BMO Capital

BMO Capital on Beam Therapeutics Inc (BEAM): 'We see BEAM-101 clinical data as positive'

Target:$57.00

+134.2%from $24.34

Sep 11, 2024Stifel Nicolaus

Beam Therapeutics Inc (BEAM) PT Raised to $69 at Stifel

Target:$69.00

+195.7%from $23.34

Feb 1, 2023Cantor Fitzgerald

Cantor Fitzgerald Initiates Coverage On Beam Therapeutics with Overweight Rating, Announces Price Target of $62

Target:$62.00

+42.7%from $43.45

Dec 20, 2022BMO Capital

BMO Capital Upgrades Beam Therapeutics Inc (BEAM) to Outperform as Risk/Reward 'Skewed to Upside'

Target:$66.00

+58.7%from $41.59

Dec 13, 2022Citigroup

Citigroup Initiates Coverage On Beam Therapeutics with Buy Rating, Announces Price Target of $62

Target:$62.00

+28.7%from $48.19

Apr 28, 2022Credit Suisse

Credit Suisse Initiates Coverage On Beam Therapeutics with Neutral Rating, Announces Price Target of $62

Target:$62.00

+55.7%from $39.83

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance